Biogen To End Investors' Alzheimer's Drug Case For $18.9M
Biogen Inc. has agreed to pay $18.9 million to exit a lawsuit accusing it of misleading investors about the commercial readiness of a new Alzheimer's treatment, according to a settlement filed...To view the full article, register now.
Already a subscriber? Click here to view full article